Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), has demonstrated promising outcomes in treating HER2-negative early-stage breast cancer with BRCA mutations. However, a comprehensive evaluation of its cost-effectiveness in the context of the United States and China has yet to be undertaken. This study seeks to fill this research void by performing a thorough cost-utility […]
The post Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States. first appeared on Physician’s Weekly.
